{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:00:17Z","timestamp":1790006417585,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Phys Eng Sci Med"],"DOI":"10.1007\/s13246-026-01805-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:03:56Z","timestamp":1790003036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transitioning from CA to NCA 177Lu in the preparation of [177Lu]Lu-DOTATATE for PRRT \u2013 observations and considerations from a retrospective review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5018-6354","authenticated-orcid":false,"given":"Luke","family":"Fincher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consulato","family":"Cara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mckay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Patrick","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"11","key":"1805_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","volume":"14","author":"M Cakir","year":"2010","unstructured":"Cakir M, Dworakowska D, Grossman A (2010) Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 14(11):2570\u20132584. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01125.x","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4274\/mirt.galenos.2021.37268","volume":"30","author":"S \u00d6zg\u00fcven","year":"2021","unstructured":"\u00d6zg\u00fcven S, Filizo\u011flu N, Kesim S et al (2021) Physiological biodistribution of 68Ga-DOTA-TATE in normal subjects. Mol Imaging Radionucl Ther 30(1):39\u201346. https:\/\/doi.org\/10.4274\/mirt.galenos.2021.37268","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"Suppl 2","key":"1805_CR3","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.2967\/jnumed.116.186502","volume":"58","author":"R Levine","year":"2017","unstructured":"Levine R, Krenning EP (2017) Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med 58(Suppl 2):3S-9S. https:\/\/doi.org\/10.2967\/jnumed.116.186502","journal-title":"J Nucl Med"},{"issue":"2","key":"1805_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.117.192203","volume":"59","author":"N Ayati","year":"2018","unstructured":"Ayati N, Lee ST, Zakavi R et al (2018) Long-acting somatostatin analog therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med 59(2):223\u2013227. https:\/\/doi.org\/10.2967\/jnumed.117.192203","journal-title":"J Nucl Med"},{"issue":"5","key":"1805_CR5","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C (2020) Somatostatin analogs in clinical practice: a review. Int J Mol Sci 21(5):1682. https:\/\/doi.org\/10.3390\/ijms21051682","journal-title":"Int J Mol Sci"},{"key":"1805_CR6","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.122.263813","author":"DK Soulek","year":"2022","unstructured":"Soulek DK, Mastascusa NJ, Martin ME, Graves SA (2022) Practical considerations for implementation of 177Lu-DOTATATE neuroendocrine tumor treatment programs. J Nucl Med Technol. https:\/\/doi.org\/10.2967\/jnmt.122.263813","journal-title":"J Nucl Med Technol"},{"issue":"7","key":"1805_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K et al (2019) NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med 60(7):937\u2013943. https:\/\/doi.org\/10.2967\/jnumed.118.230607","journal-title":"J Nucl Med"},{"key":"1805_CR8","unstructured":"Fincher L, Browne E, McKay E (2023) Changing Horses - Validating a Transition from C.A to N.C.A 177Lutetium in 177Lu-DOTATATE Therapy [Poster presentation]. Australia New Zealand Society of Nuclear Medicine Annual Scientific Meeting, 26\u201328. Adelaide, Australia"},{"issue":"1","key":"1805_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13550-022-00946-3","volume":"12","author":"H Siebinga","year":"2022","unstructured":"Siebinga H, Veerman CHAM, de Wit-van der Veen L, Stokkel MPM, Hendrikx JJMA, Aalbersberg EA (2022) Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough. EJNMMI Res 12(1):74. https:\/\/doi.org\/10.1186\/s13550-022-00946-3","journal-title":"EJNMMI Res"},{"key":"1805_CR10","unstructured":"Fincher L, Browne E, McKay E, Cara C (2024) Is Less More? Specific Activity and Peptide Concentration Effects on 177Lu-DOTATATE Biodistribution [Poster Presentation]. Engineering and Physical Sciences in Medicine and Australian Biomedical Engineering Conference, 17\u201320. Melbourne Australia"},{"key":"1805_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","volume":"102","author":"L Geenen","year":"2021","unstructured":"Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A (2021) Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 102:1\u201311. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.006","journal-title":"Nucl Med Biol"},{"issue":"2","key":"1805_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","volume":"49","author":"A Dash","year":"2015","unstructured":"Dash A, Pillai MR, Knapp FF Jr. (2015) Production of (177)Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging 49(2):85\u2013107. https:\/\/doi.org\/10.1007\/s13139-014-0315-z","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1805_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1874471008666150313111131","volume":"9","author":"WA Breeman","year":"2016","unstructured":"Breeman WA, Chan HS, de Zanger RM, Konijnenberg MK, de Blois E (2016) Overview of development and formulation of 177Lu-DOTA-TATE for PRRT. Curr Radiopharm 9(1):8\u201318. https:\/\/doi.org\/10.2174\/1874471008666150313111131","journal-title":"Curr Radiopharm"},{"issue":"1","key":"1805_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5603\/NMR.a2018.0012","volume":"21","author":"I Sarikaya","year":"2018","unstructured":"Sarikaya I, Sarikaya A, Alnafisi N, Alenezi S (2018) Significance of splenic uptake on somatostatin receptor imaging studies. Nucl Med Rev Cent East Eur 21(1):66\u201370. https:\/\/doi.org\/10.5603\/NMR.a2018.0012","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"6","key":"1805_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/RLU.0000000000004670","volume":"48","author":"D Morland","year":"2023","unstructured":"Morland D, Laures N, Triumbari EKA et al (2023) Impact of \u2018cold\u2019 somatostatin analog administration on somatostatin receptor imaging: a systematic review. Clin Nucl Med 48(6):467\u2013473. https:\/\/doi.org\/10.1097\/RLU.0000000000004670","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1805_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","volume":"37","author":"I Velikyan","year":"2010","unstructured":"Velikyan I, Sundin A, Eriksson B et al (2010) In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol 37(3):265\u2013275. https:\/\/doi.org\/10.1016\/j.nucmedbio.2009.11.008","journal-title":"Nucl Med Biol"},{"issue":"5","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-199325050-00004","volume":"25","author":"P Chanson","year":"1993","unstructured":"Chanson P, Timsit J, Harris AG (1993) Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25(5):375\u2013391. https:\/\/doi.org\/10.2165\/00003088-199325050-00004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1805_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00259-022-06094-z","volume":"50","author":"CHAM Veerman","year":"2023","unstructured":"Veerman CHAM, Siebinga H, de Vries-Huizing DMV et al (2023) The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging 50(5):1434\u20131441. https:\/\/doi.org\/10.1007\/s00259-022-06094-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1805_CR19","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.adro.2021.100761","volume":"6","author":"M Alexandru","year":"2021","unstructured":"Alexandru M, Rodica A, Dragos-Eugen G, Mihai-Teodor G (2021) Assessing the spleen as an organ at risk in radiation therapy and its relationship with radiation-induced lymphopenia: a retrospective study and literature review. Adv Radiat Oncol 6(6):100761. https:\/\/doi.org\/10.1016\/j.adro.2021.100761","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"1805_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.clon.2022.02.019","volume":"34","author":"K Keshwani","year":"2022","unstructured":"Keshwani K, Richards TM, Seddon BM, Gaze MN (2022) New guidance from the royal college of radiologists on incidental irradiation of the spleen: What does it say and why does it matter? Clin Oncol (R Coll Radiol) 34(7):436\u2013438. https:\/\/doi.org\/10.1016\/j.clon.2022.02.019","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"1805_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2014","unstructured":"Bodei L, Mueller-Brand J, Baum RP et al (2014) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(5):800\u2013816. https:\/\/doi.org\/10.1007\/s00259-012-2330-6","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Physical and Engineering Sciences in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13246-026-01805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13246-026-01805-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13246-026-01805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:03:57Z","timestamp":1790003037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13246-026-01805-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":21,"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1007\/s13246-026-01805-4","relation":{},"ISSN":["2662-4729","2662-4737"],"issn-type":[{"value":"2662-4729","type":"print"},{"value":"2662-4737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was reviewed by the South Eastern Sydney Local Health District Human Research Ethics Committee (Low Negligible Risk Committee). It was determined the project did not raise any ethical risks requiring submission to an ethical review committee in accordance with NSW Health Policy.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}